← Leaderboards
Vincent Collins Ofuka Njar
University Of Maryland Baltimore
$7,431,601
Attributed
$8,937,962
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,937,962 · 6
By mechanism
R01$5,183,102 · 2
R44$3,012,722 · 2
R21$742,138 · 2
Top collaborators
- Vidya P Ramamurthy3 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- France Carrier$2,949,818
- David Joseph Weber$22,294,951
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorPre-ClinicalPharmaceutical PreparationsEffective TherapyIn VivoNeoplasm MetastasisIn VitroIn Vivo ModelAnalogLeadToxic EffectToxicologyDoseMalignant Neoplasm Of ProstateResistanceDrug ResistanceOralDrug KineticsGrowthBaseAndrogen ReceptorPreclinical StudyMolecularOncogenic
Grant awards (18)
Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer$1,022,522
R44 · FY2025 · CA
Development of VNLG-152R as novel therapeutic for triple negative breast cancer$995,100
R44 · FY2022 · CA
Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy$639,268
R01 · FY2022 · CA · contact PI
Development of VNLG-152R as novel therapeutic for triple negative breast cancer$995,100
R44 · FY2021 · CA
Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy$448,418
R01 · FY2021 · CA · contact PI
Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy$217,522
R01 · FY2021 · CA · contact PI
Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy$448,418
R01 · FY2020 · CA · contact PI
Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy$434,965
R01 · FY2019 · CA · contact PI
Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy$448,418
R01 · FY2018 · CA · contact PI
Targeting Pancreatic Cancer with Novel Mnk-eIF4E and AR Modulating Agents$179,403
R21 · FY2016 · CA · contact PI
Targeting Pancreatic Cancer with Novel Mnk-eIF4E and AR Modulating Agents$215,284
R21 · FY2015 · CA · contact PI
Development of VN/14-1 and Related Analogs for Breast Cancer Therapy$481,921
R01 · FY2014 · CA · contact PI
Development of VN/14-1 and Related Analogs for Breast Cancer Therapy$470,795
R01 · FY2013 · CA · contact PI
Development of VN/14-1 and Related Analogs for Breast Cancer Therapy$518,423
R01 · FY2012 · CA · contact PI
Development of VN/14-1 and Related Analogs for Breast Cancer Therapy$527,599
R01 · FY2011 · CA · contact PI
Development of VN/14-1 and Related Analogs for Breast Cancer Therapy$547,355
R01 · FY2010 · CA · contact PI
Retinoids, RAMBAs, and Histone Deacetylase Inhibitors$155,886
R21 · FY2006 · CA · contact PI
Retinoids, RAMBAs, and Histone Deacetylase Inhibitors$191,565
R21 · FY2005 · CA